Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet
Taking safety, immunogenicity, and production capacity into account, the 3 μg doseof CoronaVac is the suggested dose for efficacy assessment in future phase 3 trials….
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions
-
Noosa News22 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General20 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
General24 hours agoMan dies at shopping centre car park at Charlestown following reports of assault
-
Noosa News23 hours agoSchoolgirls hit by fishtailing car in terrifying crash in Bellbird Park, Ipswich